Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364341 | 0.88 | MAP3K5 (0.38) | TAS2R8HDAC6NTRK1 | |
| SCHEMBL20162176 | 0.83 | TAS2R8 (0.40) | TAS2R8NTRK1RIPK1P2RY14 | |
| SCHEMBL21518096 | 0.78 | TAS2R8 (0.43) | TAS2R8NTRK1KDM4CKDM5AKDM5B | |
| SCHEMBL20162136 | 0.77 | HDAC1 (0.41) | TAS2R8HDAC6 | |
| SCHEMBL20162146 | 0.77 | TAS2R8 (0.51) | TAS2R8HDAC6KDM4CKDM5AKDM5B | |
| SCHEMBL20364337 | 0.76 | ESR2 (0.46) | TAS2R8HDAC6 | |
| SCHEMBL20364335 | 0.75 | MAP3K5 (0.38) | TAS2R8RIPK1 | |
| SCHEMBL20162120 | 0.75 | TAS2R8 (0.49) | TAS2R8 | |
| SCHEMBL21518085 | 0.74 | TAS2R8 (0.48) | TAS2R8NTRK1RIPK1P2RY14 | |
| SCHEMBL20162148 | 0.74 | RBP4 (0.34) | KDM4CKDM5AKDM5BKDM4ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885HDAC6 188/4885NTRK1 756/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885HDAC6 188/4885NTRK1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.